Literature DB >> 6446396

Susceptibility of anaerobic bacteria to cefoperazone and other beta-lactam antibiotics.

N V Jacobus, F P Tally, M Barza, S L Gorbach.   

Abstract

The in vitro activity of cefoperazone was tested against 155 clinical isolates of anaerobic bacteria and compared to that of cefoxitin, LY127935 (moxalactam), cefotaxime, cefamandole, and cephalothin. Against the Bacteroides fragilis group, the compound was as active as LY127935, but less active than cefoxitin. Cefotaxime was less active than cefoperazone, cefoxitin, and LY127935. Cefoperazone, as well as cefoxitin, LY127935, and cefotaxime, exhibited excellent activity against all other anaerobic organisms tested. Cefamandole and cephalothin showed inferior activity when compared to the other four drugs.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6446396

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  12 in total

1.  Interplay between the gastric bacterial microbiota and Candida albicans during postantibiotic recolonization and gastritis.

Authors:  Katie L Mason; John R Erb Downward; Nicole R Falkowski; Vincent B Young; John Y Kao; Gary B Huffnagle
Journal:  Infect Immun       Date:  2011-10-10       Impact factor: 3.441

Review 2.  The nonprophylactic role of cephalosporins in obstetrics and gynecology.

Authors:  J L LeFrock; B R Smith; A Molavi
Journal:  Bull N Y Acad Med       Date:  1984-05

3.  Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with beta-lactamase production.

Authors:  M A Crosby; D W Gump
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

4.  Factors affecting the in vitro activity of cefoperazone against the Bacteroides fragilis group.

Authors:  V L Sutter; Y Y Kwok
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

5.  Penetration of cefoperazone into surgical wound drainage in patients undergoing head and neck surgery.

Authors:  R R Muder; V L Yu; J Johnson; P Thearle; J Lyon; W Diven
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

6.  Comparative in vitro activity of ceftizoxime, cefoperazone, and cefoxitin against anaerobic bacteria.

Authors:  M W Drulak; A W Chow
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

Review 7.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

Review 8.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

9.  Tentative interpretive standards for agar disk diffusion antimicrobial susceptibility testing of cefoperazone.

Authors:  C Thornsberry; A L Barry; R N Jones; C N Baker; R E Badal
Journal:  J Clin Microbiol       Date:  1982-05       Impact factor: 5.948

10.  Cefoperazone in lower respiratory tract infections.

Authors:  C J Woods; R B Ellis-Pegler
Journal:  Drugs       Date:  1981       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.